Journal of Gastroenterology

, Volume 46, Issue 9, pp 1120–1126 | Cite as

Serodiagnosis of Helicobacter hepaticus infection in patients with liver and gastrointestinal diseases: western blot analysis and ELISA using a highly specific monoclonal antibody for H. hepaticus antigen

  • Kazunari Murakami
  • Ryoki Takahashi
  • Masami Ono
  • Koichiro Watanabe
  • Tadayoshi Okimoto
  • Masaaki Kodama
  • Daijiro Abe
  • Moto Kimura
  • Toshio Fujioka
Original Article—Liver, Pancreas, and Biliary Tract



Helicobacter hepaticus infection might be associated with liver and biliary tract diseases. To investigate its pathogenic role, the properties of anti-H. hepaticus serum antibody in patients with liver and diseases were elucidated.


Serum samples were collected from 166 patients–69 with liver diseases, 38 with upper gastrointestinal diseases, 17 with lower gastrointestinal diseases, 26 with biliary tract diseases, and 16 with pancreas diseases; 30 control sera were obtained from 30 healthy blood donors. Serum samples were analyzed by enzyme-linked immunosorbent assay (ELISA) and western blot using the new monoclonal antibody HR II-51.


Anti-H. hepaticus serum antibody concentrations in patients with liver disease (n = 69) were significantly increased compared with those in other disease groups (p = 0.014 to <0.001). Particularly, liver cirrhosis (n = 19) showed a significantly higher antibody level compared with other liver diseases (n = 50, p = 0.005) and healthy donors (n = 30, p = 0.0005), as well as a higher seroprevalence (68.4%) compared with other liver diseases (p = 0.05) and healthy donors (p = 0.004). Furthermore, the ELISA value in liver cirrhosis (n = 19) was significantly higher than that in patients with hepatitis B virus (HBV)—and/or hepatitis C virus (HCV)-infected chronic hepatitis (n = 15) (0.389 ± 0.084 vs. 0.350 ± 0.084, p = 0.029). However, there was no relationship between the total immunoglobulin concentration and the anti-H. hepaticus antibody level in each liver disease (Spearman’s rank correlation coefficient [rs] < 0.225).


H. hepaticus infection might play a role in the development of liver diseases; in particular, it might increase the risk of the development of HBV- and/or HCV-infected liver diseases.


Helicobacter hepaticus Serodiagnosis Liver diseases Gastrointestinal disease ELISA 



We thank Dr. M. Seike for collecting samples from patients, and Ms. Y. Kudo for treating the samples.

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Ward JM, Fox JG, Anver MR, Haines DC, George CV, Collins MJ Jr, Gorelick PL, et al. Chronic active hepatitis and associated liver tumors in mice caused by a persistent bacterial infection with a novel Helicobacter species. J Natl Cancer Inst. 1994;86:1222–7.PubMedCrossRefGoogle Scholar
  2. 2.
    Fox JG, Dewhirst FE, Tully JG, Paster BJ, Yan L, Taylor NS, et al. Helicobacter hepaticus sp. nov., a microaerophilic bacterium isolated from liver and intestinal mucosal scrapings from mice. J Clin Microbiol. 1994;32:1238–45.PubMedGoogle Scholar
  3. 3.
    Suerbaum S, Josenhans C, Sterzenbach T, Drescher B, Brandt P, Bell M, et al. The complete genome sequence of the carcinogenic bacterium Helicobacter hepaticus. Proc Natl Acad Sci U S A. 2003;100:7901–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Ihring M, Schrenzel MD, Fox JG. Differential susceptibility to hepatic inflammation and proliferation in AXB recombinant inbred mice chronically infected with Helicobacter hepaticus. Am J Pathol. 1999;155:571–82.CrossRefGoogle Scholar
  5. 5.
    Ward JM, Anver MR, Haines DC, Benveniste RE. Chronic active hepatitis in mice caused by Helicobacter hepaticus. Am J Pathol. 1994;145:959–68.PubMedGoogle Scholar
  6. 6.
    Fox JG, Li X, Yan L, Cahill RJ, Hurley R, Lewis R, et al. Chronic proliferative hepatitis in A/JCr mice associated with persistent Helicobacter hepaticus infection: a model of Helicobacter-induced carcinogenesis. Infect Immun. 1996;64:1548–58.PubMedGoogle Scholar
  7. 7.
    Fox JG, Dewhirst FE, Shen Z, Feng Y, Taylor NS, Paster BJ, et al. Hepatic Helicobacter species identified in bile and gallbladder tissue from Chileans with chronic cholecystitis. Gastroenterology. 1998;114:755–63.PubMedCrossRefGoogle Scholar
  8. 8.
    Pellicano R, Mazzaferro V, Grigioni WF, Cutufia MA, Fagoonee S, Silengo L, et al. Helicobacter species sequences in liver samples from patients with and without hepatocellular carcinoma. World J Gastroenterol. 2004;0:598–601.Google Scholar
  9. 9.
    Rocha M, Avenaud P, Ménard A, Le Bail B, Balabaud C, Bioulac-Sage P, et al. Association of Helicobacter species with hepatitis C cirrhosis with or without hepatocellular carcinoma. Gut. 2005;54:396–401.PubMedCrossRefGoogle Scholar
  10. 10.
    Nilsson HO, Taneera J, Castedal M, Glatz E, Olsson R, Wadström T. Identification of Helicobacter pylori, other Helicobacter species by PCR hybridization, and partial DNA sequencing in human liver samples from patients with primary sclerosing cholangitis or primary biliary cirrhosis. J Clin Microbiol. 2000;38:1072–6.PubMedGoogle Scholar
  11. 11.
    Vorobjova T, Nilsson I, Tcrjajev S, Granholm M, Lyyra M, Porkka T, et al. Serum antibodies to enterohepatic Helicobacter spp. in patients with chronic liver diseases and in population with high prevalence of H. pylori infection. Dig Liver Dis. 2006;38:171–6.PubMedCrossRefGoogle Scholar
  12. 12.
    Nilsson I, Kornilovs’ka I, Lindgren S, Ljungh Å, Wadström T. Increased prevalence of seropositivity for non-gastric Helicobacter species in patients with autoimmune liver disease. J Med Microbiol. 2003;52:949–53.PubMedCrossRefGoogle Scholar
  13. 13.
    Fukuda Y, Shimoyama T, Ohmura T, Sano Y, Nakabayashi N, Takahashi R, et al. Characterization and application of a new monoclonal antibody with high specificity for Helicobacter hepaticus. Helicobacter. 2009;4:66–71.CrossRefGoogle Scholar
  14. 14.
    Kawai T, Kawakami K, Kudo T, Ogihara S, Hada Y, Moriyasu F. A new serum antibody test kit (E plate) for evaluation of Helicobacter pylori eradication. Intern Med. 2002;10:780–3.CrossRefGoogle Scholar
  15. 15.
    Nilsson I, Lindgren S, Eriksson T, Wadström T. Serum antibodies to Helicobacter hepaticus and Helicobacter pylori in patients with chronic liver disease. Gut. 2000;46:410–4.PubMedCrossRefGoogle Scholar
  16. 16.
    Shimoyama T, Takahashi R, Abe D, Mizuki D, Endo T, Fukuda S. Serological analysis of Helicobacter hepaticus infection in patients with biliary and pancreatic diseases. J Gastroenterol Hepatol. 2010;25:S86–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Fox JG, Feng Y, Theve EJ, Raczynski AR, Fiala JLA, Doernte AL, et al. Gut microbes define liver cancer risk in mice exposed to chemical and viral transgenic hepatocarcinogens. Gut. 2010;59:88–97.PubMedCrossRefGoogle Scholar
  18. 18.
    Huong Y, Fan XG, Wang ZM, Zhou JH, Tian XF, Li N. Identification of Helicobacter species in human liver samples from patients with primary hepatocellular carcinoma. J Clin Pathol. 2004;57:1273–7.CrossRefGoogle Scholar

Copyright information

© Springer 2011

Authors and Affiliations

  • Kazunari Murakami
    • 1
  • Ryoki Takahashi
    • 2
  • Masami Ono
    • 1
  • Koichiro Watanabe
    • 1
  • Tadayoshi Okimoto
    • 1
  • Masaaki Kodama
    • 1
  • Daijiro Abe
    • 2
  • Moto Kimura
    • 2
  • Toshio Fujioka
    • 1
  1. 1.Department of Gastroenterology, Faculty of MedicineOita UniversityYuhuJapan
  2. 2.Wakamoto Pharmaceutical Co., Ltd., Sagami Research LaboratoriesAshigarakami-gunJapan

Personalised recommendations